Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + rituximab + lenalidomide for relapsed/refractory diffuse large B-cell lymphoma
ChiCTR1900024918Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, rituximab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective response rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
tucidinostatrituximablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900024918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024918.